文献速递基础与转化研究临床试验与 GCP

自体P63+肺祖细胞移植治疗慢性阻塞性肺疾病

Autologous transplantation of P63+ lung progenitor cells for chronic obstructive pulmonary disease therapy.
PubMed 文献 · Sci Transl Med · 2024-02-14

一项临床试验在28例II至IV期慢性阻塞性肺疾病(COPD)受试者中经支气管镜行肺内自体P63+祖细胞移植,细胞经支气管刷检分离、培养3至5周后按0.7×10^6至5.2×10^6个/千克体重回输。研究终点20例可评估(干预组17例、对照组3例),未发生3至5级不良事件或严重不良事件;移植24周后干预组DLCO较基线变化+18.2%,对照组为-17.4%(P=0.008),干预组6分钟步行距离增加超过30米。

要点

  • 自体P63+肺祖细胞经支气管镜移植未发生3至5级不良事件或严重不良事件。
  • 移植24周后干预组DLCO较基线变化+18.2%,对照组为-17.4%(P=0.008)。
  • 干预组6分钟步行距离增加超过30米,P63表达较高与疗效相关。

核心结论

  • 培养的自体P63+肺祖细胞移植是安全的,可能成为COPD的潜在治疗策略。

研究设计与样本

  • 临床试验在28例II至IV期COPD受试者中经支气管镜行肺内自体P63+祖细胞移植,细胞从干预组受试者气道基底层经支气管刷检分离、培养3至5周后回输。
  • 回输剂量为0.7×10^6至5.2×10^6个细胞/千克体重,研究终点可评估20例(干预组17例、对照组3例)。

主要发现

  • 未发生3至5级不良事件或严重不良事件;干预组记录了支气管镜相关不良事件,其他不良事件两组间无实质差异。
  • 移植24周后干预组DLCO较基线变化+18.2%,对照组为-17.4%(P=0.008)。
  • 干预组6分钟步行距离增加超过30米。
  • 干预组中应答者与无应答者分离的祖细胞转录组分析显示,P63表达较高与治疗疗效相关。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Adult lung resident stem/progenitor cells, including P63+ progenitor cells, have demonstrated the capacity for regeneration of lung epithelium in preclinical models. Here, we report a clinical trial of intrapulmonary P63+ progenitor cell transplantation in 28 participants with stage II to IV chronic obstructive pulmonary disease (COPD). Autologous P63+ progenitor cells were isolated from the airway basal layer of participants in the intervention group via bronchoscopic brushing, cultured for 3 to 5 weeks, and then transplanted back into the lungs via bronchoscopy at 0.7 × 106 to 5.2 × 106 cells per kilogram of body weight. Twenty patients were evaluable at the end of the study (intervention group, n = 17; control group, n = 3). No grade 3 to 5 adverse events (AEs) or serious AEs occurred. Although bronchoscopy-associated AEs were recorded in participants in the intervention group, other AEs were not substantial different between groups. Twenty-four weeks after transplantation, participants in the intervention group displayed improvement in gas transfer capacity [diffusing capacity of the lung for carbon monoxide (DLCO) change from baseline: +18.2%], whereas the control group experienced a decrease (DLCO change from baseline: -17.4%; P = 0.008). Furthermore, participants in the intervention group showed >30-meter increase in walking distance within 6 minutes. Transcriptomic analysis of progenitor cells isolated from responding and nonresponding individuals in the intervention group showed that higher expression of P63 was associated with treatment efficacy. In conclusion, transplantation of cultured P63+ lung progenitor cells was safe and might represent a potential therapeutic strategy for COPD.

来源:Sci Transl Med,查看原文。版权归原作者所有。

引用

  1. Wang Y, Meng Z, Liu M, et al. Autologous transplantation of P63+ lung progenitor cells for chronic obstructive pulmonary disease therapy. Sci Transl Med. 2024. PMID: 38354225. doi:10.1126/scitranslmed.adi3360

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。